Nuclear Medicine and Biology
Volume 35, Issue 8 , Pages 883-893 , November 2008

Pharmacokinetics, micro-SPECT/CT imaging and therapeutic efficacy of 188Re-DXR-liposome in C26 colon carcinoma ascites mice model

  • Liang-Cheng Chen

      Affiliations

    • Institute of Nuclear Energy Research, Taoyuan, Taiwan
    • ,
  • Chih-Hsien Chang

      Affiliations

    • Institute of Nuclear Energy Research, Taoyuan, Taiwan
    • ,
  • Chia-Yu Yu

      Affiliations

    • Institute of Nuclear Energy Research, Taoyuan, Taiwan
    • ,
  • Ya-Jen Chang

      Affiliations

    • Institute of Nuclear Energy Research, Taoyuan, Taiwan
    • ,
  • Yu-Hsien Wu

      Affiliations

    • Institute of Nuclear Energy Research, Taoyuan, Taiwan
    • ,
  • Wan-Chi Lee

      Affiliations

    • Institute of Nuclear Energy Research, Taoyuan, Taiwan
    • ,
  • Chung-Hsin Yeh

      Affiliations

    • Institute of Nuclear Energy Research, Taoyuan, Taiwan
    • ,
  • Te-Wei Lee

      Affiliations

    • Institute of Nuclear Energy Research, Taoyuan, Taiwan
    • ,
  • Gann Ting

      Affiliations

    • National Institute of Cancer Research, National Health Research Institutes, Miaoli, Taiwan
    • Corresponding Author InformationCorresponding author. National Institute of Cancer Research, National Health Research Institutes, Veterans General Hospital-Taipei 201, Beitou Taipei 112, Taiwan, ROC. Tel.: +886 2 28712121; fax: +886 2 28716467.

Received 18 July 2008 ,Revised 25 August 2008 ,Accepted 13 September 2008.

References 

  1. Dancey JE, Chen HX. Strategies for optimizing combinations of molecularly targeted anticancer agents. Nat Rev Drug Discov. 2006;5:649–659
  2. Choy H, Kim DW. Chemotherapy and irradiation interaction. Semin Oncol. 2003;30:3–10
  3. Jain RK. Normalizing tumor vasculature with anti-angiogenic therapy: a new paradigm for combination therapy. Nat Med. 2001;7:987–989
  4. Huber PE, Bischof M, Jenne J, Heiland S, Peschke P, Saffrich R, et al. Trimodal cancer treatment: beneficial effects of combined antiangiogenesis, radiation, and chemotherapy. Cancer Res. 2005;65:3643–3655
  5. Wong JY. Systemic targeted radionuclide therapy: potential new areas. Int J Radiat Oncol Biol Phys. 2006;66:S74–S82
  6. Eisenberg B, Decosse JJ, Harford F, Michalek J. Carcinoma of the colon and rectum: the natural history reviewed in 1704 patients. Cancer. 1982;49:1131–1134
  7. Zebrowski BK, Liu W, Ramirez K, Akagi Y, Mills GB, Ellis LM. Markedly elevated levels of vascular endothelial growth factor in malignant ascites. Ann Surg Oncol. 1999;6:373–378
  8. Pestieau SR, Sugarbaker PH. Treatment of primary colon cancer with peritoneal carcinomatosis: comparison of concomitant vs. delayed management. Dis Colon Rectum. 2000;43:1341–1346[discussion 1347–8]
  9. Markman M. Intraperitoneal chemotherapy in the management of colon cancer. Semin Oncol. 1999;26:536–539
  10. Allen TM, Cullis PR. Drug delivery systems: entering the mainstream. Science. 2004;303:1818–1822
  11. Torchilin VP. Recent advances with liposomes as pharmaceutical carriers. Nat Rev Drug Discov. 2005;4:145–160
  12. Gabizon A, Shmeeda H, Barenholz Y. Pharmacokinetics of pegylated liposomal Doxorubicin: review of animal and human studies. Clin Pharmacokinet. 2003;42:419–436
  13. Syrigos KN, Vile RG, Peters AM, Harrington KJ. Biodistribution and pharmacokinetics of 111In-dTPA-labelled pegylated liposomes after intraperitoneal injection. Acta Oncol. 2003;42:147–153
  14. Speyer JL. The rationale behind intraperitoneal chemotherapy in gastrointestinal malignancies. Semin Oncol. 1985;12:23–28
  15. Cabanes A, Tzemach D, Goren D, Horowitz AT, Gabizon A. Comparative study of the antitumor activity of free doxorubicin and polyethylene glycol-coated liposomal doxorubicin in a mouse lymphoma model. Clin Cancer Res. 1998;4:499–505
  16. Sadzuka Y, Hirota S, Sonobe T. Intraperitoneal administration of doxorubicin encapsulating liposomes against peritoneal dissemination. Toxicol Lett. 2000;116:51–59
  17. Koppe MJ, Bleichrodt RP, Soede AC, Verhofstad AA, Goldenberg DM, Oyen WJ, et al. Biodistribution and therapeutic efficacy of 125/131I-, 186Re-, 88/90Y-, or 177Lu-labeled monoclonal antibody MN-14 to carcinoembryonic antigen in mice with small peritoneal metastases of colorectal origin. J Nucl Med. 2004;45:1224–1232
  18. Miao Y, Owen NK, Fisher DR, Hoffman TJ, Quinn TP. Therapeutic efficacy of a 188Re-labeled alpha-melanocyte-stimulating hormone peptide analog in murine and human melanoma-bearing mouse models. J Nucl Med. 2005;46:121–129
  19. McQuarrie S, Mercer J, Syme A, Suresh M, Miller G. Preliminary results of nanopharmaceuticals used in the radioimmunotherapy of ovarian cancer. J Pharm Pharm Sci. 2005;7:29–34
  20. Iznaga-Escobar N. 188Re-Direct labeling of monoclonal antibodies for radioimmunotherapy of solid tumors: biodistribution, normal organ dosimetry, and toxicology. Nucl Med Biol. 1998;25:441–447
  21. Chen LC, Chang CH, Yu CY, Chang YJ, Hsu WC, Ho CL, et al. Biodistribution, pharmacokinetics and imaging of 188Re-BMEDA-labeled pegylated liposomes after intraperitoneal injection in a C26 colon carcinoma ascites mouse model. Nucl Med Biol. 2007;34:415–423
  22. Bartlett GR. Phosphorus assay in column chromatography. J Biol Chem. 1959;234:466–468
  23. Reilly RM, Chen P, Wang J, Scollard D, Cameron R, Vallis KA. Preclinical pharmacokinetic, biodistribution, toxicology, and dosimetry studies of 111In-DTPA-human epidermal growth factor: an Auger electron-emitting radiotherapeutic agent for epidermal growth factor receptor-positive breast cancer. J Nucl Med. 2006;47:1023–1031
  24. Chang CH, Wang HE, Wu SY, Fan KH, Tsai TH, Lee TW, et al. Comparative evaluation of FET and FDG for differentiating lung carcinoma from inflammation in mice. Anticancer Res. 2006;26:917–925
  25. Andersen PK, Borgan O, Gill RD, Keiding N. Statistical Models Based on Counting Processes. New York: Springer-Verlag; 1993;
  26. Chang CH, Stabin MG, Chang YJ, Chen LC, Chen MH, Chang TJ, et al. Comparative dosimetric evaluation of nanotargeted 188Re-(DXR)-liposome for internal radiotherapy. Cancer Biother Radiopharm. 2008;[in press]
  27. Olfert ED, Cross BM, Mcwilliam AA. Guide to the Care and Use of Experimental Animals. Ottawa (Ontario, Canada): Canadian Council on Animal Care; 1993;
  28. Tseng YL, Hong RL, Tao MH, Chang FH. Sterically stabilized anti-idiotype immunoliposomes improve the therapeutic efficacy of doxorubicin in a murine B-cell lymphoma model. Int J Cancer. 1999;80:723–730
  29. Corbett TH, Griswold DP, Roberts BJ, Peckham JC, Schabel FM. Evaluation of single agents and combinations of chemotherapeutic agents in mouse colon carcinomas. Cancer. 1977;40:2660–2680
  30. Bao A, Goins B, Klipper R, Negrete G, Phillips WT. 186Re-Liposome labeling using 186Re-SNS/S complexes: in vitro stability, imaging, and biodistribution in rats. J Nucl Med. 2003;44:1992–1999
  31. Bao A, Goins B, Klipper R, Negrete G, Phillips WT. Direct 99mTc labeling of pegylated liposomal doxorubicin (Doxil) for pharmacokinetic and non-invasive imaging studies. J Pharmacol Exp Ther. 2004;308:419–425
  32. Chang YJ, Chang CH, Chang TJ, Yu CY, Chen LC, Jan ML, et al. Biodistribution, pharmacokinetics and microSPECT/CT imaging of 188Re-bMEDA-liposome in a C26 murine colon carcinoma solid tumor animal model. Anticancer Res. 2007;27:2217–2225
  33. Bally MB, Masin D, Nayar R, Cullis PR, Mayer LD. Transfer of liposomal drug carriers from the blood to the peritoneal cavity of normal and ascitic tumor-bearing mice. Cancer Chemother Pharmacol. 1994;34:137–146
  34. Gabizon AA. Selective tumor localization and improved therapeutic index of anthracyclines encapsulated in long-circulating liposomes. Cancer Res. 1992;52:891–896
  35. Zavaleta CL, Phillips WT, Bradley YC, McManus LM, Jerabek PA, Goins BA. Characterization of an intraperitoneal ovarian cancer xenograft model in nude rats using noninvasive microPET imaging. Int J Gynecol Cancer. 2007;17:407–417
  36. Janssen ML, Pels W, Massuger LF, Oyen WJ, Boonstra H, Corstens FH, et al. Intraperitoneal radioimmunotherapy in an ovarian carcinoma mouse model: effect of the radionuclide. Int J Gynecol Cancer. 2003;13:607–613
  37. Kinuya S, Yokoyama K, Izumo M, Sorita T, Obata T, Mori H, et al. Locoregional radioimmunotherapy with 186Re-labeled monoclonal antibody in treating small peritoneal carcinomatosis of colon cancer in mice in comparison with 131I-counterpart. Cancer Lett. 2005;219:41–48

PII: S0969-8051(08)00197-2

doi: 10.1016/j.nucmedbio.2008.09.005

Nuclear Medicine and Biology
Volume 35, Issue 8 , Pages 883-893 , November 2008

Article Tools

* Image Usage & Resolution